Meta-analysis · people

Semaglutide: 11.85% more weight loss than placebo without diabetes

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

Pooled trial data in people without diabetes show clear extra weight loss over placebo, along with a higher risk of gut side effects, stopping treatment and serious events such as pancreatitis and gallstones.

Kind
Meta-analysis
Studied in
People
Number studied
3613
Published
2022
Journal
J ASEAN Fed Endocr Soc

What they tested

The team wanted to know how well semaglutide shots work for weight loss in people with obesity who don't have diabetes, and how safe they are.

How the study was done

A systematic review and meta-analysis, which pools the results of several studies, of 4 randomized controlled trials with 3,613 people with obesity and no diabetes. It compared semaglutide given as an injection under the skin with placebo, a dummy shot.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Across the pooled trials, people on semaglutide lost 11.85% more of their starting weight than those on placebo (95% CI -12.81 to -10.90). Stomach and gut side effects were more common with semaglutide, with a risk ratio, the risk compared with placebo, of 1.59. Stopping treatment because of side effects had a risk ratio of 2.19, and serious side effects had a risk ratio of 1.60. Most serious events involved the gut, liver or gallbladder, such as acute pancreatitis, an inflamed pancreas, and gallstones.

What it doesn’t show

The analysis rests on only 4 trials and covers only semaglutide given as a shot under the skin. It doesn't apply to people with type 2 diabetes, who were not included.

The paper

Tan et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo